Zealand Pharma | Sustainability Performance
Zealand Pharma A/S specializes in the development of peptide-based therapeutics. The company focuses on creating innovative treatments for metabolic and gastrointestinal diseases, leveraging its expertise in biotechnology.
1998
Denmark
201 - 500 employees
Biotechnology
$1B - 10B in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#566
Overallⓘ#11
in Denmarkⓘ#7
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsDigital emissionsEnergy consumptionWaste ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Leading
Leading
Critical
Intensity
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
191.4
B/M 128.6
0.0
B/M 0.0
Powered by illuminem and GIST Impact
Controversy level
- Zealand Pharma's peptide-based drug candidates faced clinical trial safety monitoring requirements for novel metabolic treatments.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.